Back to top
more

Moderna, Inc. (MRNA)

(Real Time Quote from BATS)

$160.25 USD

160.25
27,408,749

-2.59 (-1.59%)

Updated May 6, 2021 03:27 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 13% (222 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Will Moderna (MRNA) Beat Estimates Again in Its Next Earnings Report?

Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

Is (MRNA) Outperforming Other Medical Stocks This Year?

Moderna (MRNA) Beats Q1 Earnings Estimates

Moderna (MRNA) delivered earnings and revenue surprises of 39.22% and -1.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Moderna (MRNA) closed at $162.84 in the latest trading session, marking a -6.19% move from the prior day.

Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

Google, Travelzoo, Moderna, Merck and Milestone Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

John Blank headshot

Will Central Banks Start to Care About Fundamentals?

Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.

Mark Vickery headshot

Markets Up to Start Another Busy Week

With Q1 earnings season continuing to unfold favorably (for the most part), investors look to enjoy a healthy Q2, as well.

Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?

Investors are likely to focus on any updated outlook for Modena's (MRNA) authorized coronavirus vaccine and developmental progress with new COVID-19 vaccine candidate on the first-quarter earrings call.

Neena Mishra headshot

Best Biotech Stocks & ETFs for mRNA, Gene Editing

Here is what you should know about investing in these life changing technologies.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Moderna (MRNA) closed at $175.67 in the latest trading session, marking a -1.68% move from the prior day.

Moderna (MRNA) Reports Next Week: Wall Street Expects Earnings Growth

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: NVIDIA, Booking Holdings, Altria Group, Moderna and Phillips 66

The Zacks Analyst Blog Highlights: NVIDIA, Booking Holdings, Altria Group, Moderna and Phillips 66

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

Smart Beta ETF report for FAD

Mark Vickery headshot

Top Analyst Reports for NVIDIA, Booking Holdings & Altria

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Booking Holdings (BKNG), and Altria Group (MO).

Moderna (MRNA) Stock Moves -0.83%: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $168.10, marking a -0.83% move from the previous day.

Ocugen (OCGN) Up on Positive Data for COVID-19 Vaccine Candidate

Ocugen (OCGN) gains as partner Bharat Biotech shared positive results of the second interim analysis of its phase III study of COVAXIN.

J&J (JNJ) Gets Usage Guidance for COVID-19 Vaccine in Europe

J&J (JNJ) is set to resume shipments of its COVID-19 vaccine to European countries, following positive recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC).

Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe

Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.

Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer

Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Moderna (MRNA) closed the most recent trading day at $159.87, moving -0.1% from the previous trading session.

Moderna (MRNA) Gives Pipeline Update, to Initiate New Pivotal Study

Moderna (MRNA) is developing 14 mRNA-based vaccine candidates in different stages of clinical development. Interim data from ongoing cytomegalovirus and RSV vaccine studies are promising.

SMART Global, General Motors, Moderna, BioNTech and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

SMART Global, General Motors, Moderna, BioNTech and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

Sweta Killa headshot

JNJ Vaccine Pause Gives Stay-at-Home ETFs a Shot in the Arm

The U.S. regulators recommended an immediate pause on the use of Johnson & Johnson's (JNJ) COVID- 19 vaccine over reports of a "rare and severe type of blood clot" in six out of millions vaccinated.

Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat

Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.